Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy Frozen Product
← catalyst calendarNCT06790498 · readout in 1,381 d
Sponsored by Prokidney (industry) · PROK — their whole pipeline →.
Phase
—
Status
Enrolling by invitation
Study type
Observational
Enrollment
50estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-23 | actual | When the study began enrolling |
| Primary completion | 2030-05-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-08-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-01-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Diabetic Kidney Disease
- Chronic Kidney Disease
Intervention
- Biological: Renal Autologous Cell Therapy (REACT)
Primary outcome
what the primary-completion date above is the date OFLong-term safety of REACT follow-up after completing their enrollment in the investigational clinical studies.
measured 60 months from completion of parent protocol EOS Visit
Permalink · PROK's whole pipeline · Catalyst calendar · Every registered study · What changed